Tagged: teva RSS Toggle Comment Threads | Keyboard Shortcuts

  • lauren blanchard 1:22 pm on November 26, 2015 Permalink
    Tags: CGRP antagonists, Heptares Therapeutics, , migrane, small-molecule calcitonin gene-related peptide antagonists, teva, teva migrane treatment, teva migrane uk investment, teva pharma uk investment   

    Teva Invests $10M In Heptares’ Migraine Treatment 

    tevaNovember 26, 2015 | Israeli pharmaceutical giant Teva and UK-based Heptares Therapeutics, a unit of Sosei Group Corporation, have announced a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine headaches. Heptares will receive an upfront payment of $10 million, and will be eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the partnership.

  • lauren blanchard 11:21 am on October 19, 2015 Permalink
    Tags: Fresenius, kidney dialysis, kidney dialysis israel, Nephromor, renal dialysis israel, teva, teva dialysis   

    Report: Teva Sells Dialysis Division For $90M 

    tevaOctober 19, 2015 | German dialysis company Fresenius Medical Care has acquired the Nephromor chain of community dialysis centers, owned by Israeli pharmaceutical giant Teva and Israeli healthcare service provider Clalit, Globes reports. The sale price is estimated to be between $70 and $90 million. Founded in 1994, Nephromor provides dialysis services – a life-support treatment that supports the functioning of impaired kidneys.

  • lauren blanchard 2:03 pm on October 12, 2015 Permalink
    Tags: , pharma m and a, pharma m&a, pharma news, tase listing, , teva   

    Myaln Files Request To List On Tel Aviv Stock Exchange 

    MylanOctober 12, 2015 | Dutch drug-maker Mylan formally filed a request to list on the Tel Aviv Stock Exchange (TASE) as part of the company’s ongoing hostile bid for the Irish pharmaceutical Perrigo, which also trades on the TASE. Israeli pharma companies made M&A headlines earlier this year when Teva pursued a hostile takeover of Mylan, and in order to fend off the bid, Mylan pursued its own hostile takeover of Perrigo. Teva has since abandoned its bid in favor of Allergan’s generic drug business. However, Mylan has stayed its course and become engrossed in a legal battle, in which both Mylan and Perrigo have filed suits regarding share purchases in US district courts.

  • einat 4:46 pm on March 30, 2015 Permalink
    Tags: , Israeli pharmaceutical company, teva, Teva acquisition of Auspex   

    Teva To Acquire Auspex For $3.5B 

    tevaMarch 30, 2015 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals for $3.5 billion. The acquisition will strengthen Teva’s portfolio of treatments for the central nervous system. Teva was originally founded in 1901 as Salomon, Levin, and Elstein.

  • mayay 1:00 pm on November 5, 2014 Permalink
    Tags: , , Laquinimod, teva, teva huntington's disease treatment, teva neurodegenerative drugs, teva ppms treatment   

    Teva Begins Phase II Trials On Laquinimod Drug For MS, Huntington’s Disease 

    tevaNovember 5, 2014 | The Israeli pharmaceutical company Teva and Active Biotech will expand the Laquinimod clinical development program into Phase II trials. The trials will evaluate the ability of the Laquinimod drug to treat primary progressive multiple sclerosis (PPMS) as well as Huntington’s disease. This would be the first treatment for both PPMS and Huntington’s disease beyond symptom management. The study, called ARPEGGIO, will evaluate the efficacy, safety and tolerability of the Laquinimod drug in patients with PPMS, and the LEGATO-HD trial will test the efficacy and safety of the drug use on individuals with Huntington’s disease. Teva Pharmaceutical Industries was founded in 1901 by Eli Hurvitz.

  • mayay 1:42 pm on September 3, 2014 Permalink
    Tags: advanced asthma solutions, ashtma treatments, , , phase III trial, teva, teva asthma treatments,   

    Teva Reports Successful Phase III Trials For Asthma Drug 

    Teva Makes $149M Offer For American Company NuPatheSeptember 3, 2014 | Teva Pharmaceutical Industries reported that its reslizumab asthma treatment saw positive Phase III trial results. According to the company, the drug was able to prevent serious asthma attacks in two of the case studies for the Phase III trial, showing a reduction in the number of attacks by 50 to 60 percent. “The consistent results from these duplicate Phase III trials demonstrating substantial reductions in asthma exacerbations are impressive,” said Professor Mario Castro, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine and lead investigator. Teva was founded in 1901 and is currently headed by CEO Erez Vigodman.

  • mayay 1:33 pm on August 27, 2014 Permalink
    Tags: , indian-israeli partnerships, , pharmaceuticals israel, teva, teva anti-cancer drug, venus remedies   

    Teva And Venus Remedies Partner On Anti-Cancer Drug 

    Teva Makes $149M Offer For American Company NuPatheAugust 27, 2014 | Teva Pharmaceuticals and Indian company Venus Remedies entered into a collaborative agreement for the sale of an anti-cancer drug in the Canadian market. According to the agreement, Venus Remedies will manufacture the drug and will assist Teva in registering the drug in Canada. Venus will also use its manufacturing capabilities to support Teva enhance its business in the Canadian market. Teva is an international pharmaceutical company headquartered in Petah Tikvah, Israel, founded in 1901.

  • mayay 3:59 pm on June 11, 2014 Permalink | Reply
    Tags: , , , , incubators, , , teva   

    Chief Scientist Annouces Philips-Teva and Strauss Group-Run Incubators 

    Chief Scientist Receives An Additional Budget Of NIS 250MJune 11, 2014 | According to Globes, the Office of the Chief Scientist in the Ministry of the Economy has chosen two new technology incubator franchises, which include Philips and Teva Pharmaceutical Industries as well as Strauss Group. The Phillips-Teva incubator will operate an incubator called Inspire Healthcare Innovations that will invest in pharmaceutical developments and medical devices, with an emphasis on digital platforms. The other incubator run by the Strauss Group will invest in food-related technology in fields spanning from agriculture, to production processes, to packaging.

  • mayay 12:49 pm on June 5, 2014 Permalink | Reply
    Tags: headaches, labrys, , , teva,   

    Teva Acquires Labrys Biologics For As Much As $825M 

    Teva - News Flash - IsraelJune 5, 2014 | Teva Pharmaceutical Industries acquired Labrys Biologics for up to $825 million, according to Globes. The leading Israeli pharmaceutical company reportedly payed Labrys $200 million in cash upfront and will pay up to $625 million in contingent payments following launch.

    Labrys Biologics is a private biotechnological company focused on treatments for chronic and episodic migraine headaches. The acquisition of the company aids in Teva’s goal of becoming a world leader in pain by the year 2020.

  • NoCamels Team 4:22 pm on July 23, 2013 Permalink | Reply
    Tags: , , teva   

    Teva To Grant $15M To Brain Researchers 

    Teva To Grant $15M To Brain ResearchersIsraeli pharmaceutical giant Teva has announced that it will strategically focus on Israeli brain research over the next five years. The company has allocated a $15 million fund that will be granted to both researches that are near completion and ones that are in their early stages, but show potential.

compose new post
next post/next comment
previous post/previous comment
show/hide comments
go to top
go to login
show/hide help
shift + esc